Clinical stage pharmaceutical development company
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported on Friday that it had completed enrollment in its Phase 2 NP-120 idiopathic pulmonary fibrosis (IPF) and chronic cough study.
This human trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough.
The company’s CEO, Christopher J. Moreau said in a news release – “We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data.”
To read more about this study, click
here.
There are seven sites in total participating in the study with five located in Australia and two in New Zealand. The company is projecting a data readout in calendar Q2, 2022.
The drug re-purposing company
made news recently when received a notice of allowance for Ifenprodil patent application for IPF in late January 2022.
For more on this company, visit
algernonpharmaceuticals.com.
To learn about some of the most-talked about Healthcare stocks on Stockhouse, check out the Healthcare Bullboards.
For more of the latest info on Healthcare stocks, check out the Healthcare Trending News hub on Stockhouse.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.